Image
Heike E Daldrup-Link
Professor, Radiology - Pediatric Radiology
Professor (By courtesy), Pediatrics - Hematology & Oncology
Member, Bio-X
Member, Maternal & Child Health Research Institute (MCHRI)
Member, Stanford Cancer Institute
Member, Wu Tsai Neurosciences Institute
Fellowship: UCSF Dept of Radiology (1997) CA
Board Certification: American Board of Radiology, Pediatric Radiology (2019)
CAQ, American Board of Radiology, Continued added qualification in Pediatric Radiology (2019)
Board Certification: American Board of Radiology, Diagnostic Radiology (2015)
Fellowship: Schwabing Children's Hospital Kinderklinkik Schwabing (2003) Germany
Radiology Board Certification, Bavarian Medical Association (Bayerische Landesärztekammer; BLÄK), Radiology (2001)
Residency: Technical University of Munich (2001) Germany
Residency: University of Munster Medical School (2000) Germany
Internship: University of Munster Medical School (1995) Germany
Medical Education: University of Munster Medical School (1993) Germany
Affiliation:
Committee:
Heike Elisabeth Daldrup-Link is a clinician-scientist in the Department of Radiology at Stanford University with subspecialisation in pediatric radiology, pediatric oncology imaging, and molecular imaging. Dr. Daldrup-Link trained at the University of Münster and the Technical University of Munich, Germany. She worked as an Assistant and Associate Professor at the University of California, San Francisco from 2003 to 2010, before joining Stanford Radiology in 2010. Her research interest focuses on the development of novel pediatric molecular imaging techniques, which interface observations of living cells with nanoparticle development and multimodality imaging technologies:
Dr. Daldrup-Link developed several novel concepts for pediatric oncology imaging, such as tumor characterization through the EPR effect (US6009342-A), MR imaging of tumor associated inflammation with iron oxide nanoparticles (Clin Ca Res 2011 and 2018), image-guided cancer therapy without side effects through tumor-enzyme activated theranostic nanoparticles (Small 2014 and Molecular Oncology 2019) and radiation-free whole body staging of children with cancer (Lancet Oncology 2014 and Radiology 2020). Dr. Daldrup-Link’s cellular imaging studies also yielded several new and patented ideas for in vivo imaging of stem cell transplants establishing immediately clinically applicable technologies for: in vivo stem cell tracking with FDA-approved nanoparticles (US14/161,315), in vivo imaging of stem cell rejection processes with immune-cell targeted tracers, and MRI-detection of stem cell apoptosis with enzyme-activatable contrast agents (ACS Nano 2015) and iron oxide nanoparticle-enhanced MRI (Radiology 2019 and Theranostics 2020). Over the past 10 years, Dr. Daldrup-Link's team has received 77 honors and awards for innovative cellular imaging research.
Dr. Daldrup-Link developed several novel concepts for pediatric oncology imaging, such as tumor characterization through the EPR effect (US6009342-A), MR imaging of tumor associated inflammation with iron oxide nanoparticles (Clin Ca Res 2011 and 2018), image-guided cancer therapy without side effects through tumor-enzyme activated theranostic nanoparticles (Small 2014 and Molecular Oncology 2019) and radiation-free whole body staging of children with cancer (Lancet Oncology 2014 and Radiology 2020). Dr. Daldrup-Link’s cellular imaging studies also yielded several new and patented ideas for in vivo imaging of stem cell transplants establishing immediately clinically applicable technologies for: in vivo stem cell tracking with FDA-approved nanoparticles (US14/161,315), in vivo imaging of stem cell rejection processes with immune-cell targeted tracers, and MRI-detection of stem cell apoptosis with enzyme-activatable contrast agents (ACS Nano 2015) and iron oxide nanoparticle-enhanced MRI (Radiology 2019 and Theranostics 2020). Over the past 10 years, Dr. Daldrup-Link's team has received 77 honors and awards for innovative cellular imaging research.